• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

enGene Therapeutics Inc. - Common Stock (NQ:ENGN)

7.200 -0.070 (-0.96%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about enGene Therapeutics Inc. - Common Stock

< Previous 1 2 Next >
News headline image
enGene Announces Name Change to enGene Therapeutics Inc.
April 07, 2026
From enGene Therapeutics Inc.
Via Business Wire
News headline image
enGene Reports First Quarter 2026 Financial Results and Provides Business Update
March 09, 2026
From enGene Holdings Inc.
Via Business Wire
News headline image
enGene to Participate in Upcoming Investor Conferences
February 20, 2026
From enGene Holdings Inc.
Via Business Wire
News headline image
enGene to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
February 04, 2026
From enGene Holdings Inc.
Via Business Wire
News headline image
enGene Announces Expanded $125 Million Debt Facility with Hercules Capital, Inc.
January 20, 2026
From enGene Holdings Inc.
Via Business Wire
News headline image
enGene Reports Full Year 2025 Financial Results and Provides Business Update
December 22, 2025
From enGene Holdings Inc.
Via Business Wire
News headline image
enGene’s Detalimogene Selected for FDA Manufacturing Pilot Program to Support Manufacturing Readiness
December 02, 2025
From enGene Holdings Inc.
Via Business Wire
News headline image
enGene to Present at the Piper Sandler 37th Annual Healthcare Conference
November 25, 2025
From enGene Holdings Inc.
Via Business Wire
News headline image
enGene Announces Pricing of $130 Million Public Offering of Common Shares and Pre-Funded Warrants
November 13, 2025
From enGene Holdings Inc.
Via Business Wire
News headline image
enGene Announces Proposed Public Offering of Common Shares
November 12, 2025
From enGene Holdings Inc.
Via Business Wire
News headline image
Detalimogene Demonstrates Improved Complete Response Rate of 62% at 6 Months
November 11, 2025
From enGene Holdings Inc.
Via Business Wire
News headline image
enGene to Host Conference Call to Provide Update on Pivotal Cohort of LEGEND Trial
November 10, 2025
From enGene Holdings Inc.
Via Business Wire
News headline image
enGene to Participate in Upcoming Investor Conferences
November 06, 2025
From enGene Holdings Inc.
Via Business Wire
News headline image
enGene Named a BioSpace 2026 Best Places to Work Winner
November 04, 2025
From enGene Holdings Inc.
Via Business Wire
News headline image
enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
October 01, 2025
From enGene Holdings Inc.
Via Business Wire
News headline image
enGene Appoints Hussein Sweiti, M.D., MSc, as Chief Medical Officer
September 30, 2025
From enGene Holdings Inc.
Via Business Wire
News headline image
enGene Reports Third Quarter 2025 Financial Results and Provides Business Update
September 11, 2025
From enGene Holdings Inc.
Via Business Wire
News headline image
enGene Achieves Target Enrollment Milestone for LEGEND Trial Pivotal Cohort
September 03, 2025
From enGene Holdings Inc.
Via Business Wire
News headline image
enGene to Participate in Upcoming Investor Conferences
August 27, 2025
From enGene Holdings Inc.
Via Business Wire
News headline image
enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
August 04, 2025
From enGene Holdings Inc.
Via Business Wire
News headline image
enGene Announces Board and Leadership Appointments to Support Commercial Readiness
July 08, 2025
From enGene Holdings Inc.
Via Business Wire
News headline image
FDA Grants RMAT Designation for enGene’s Detalimogene, Enabling Potential for Expedited Review in High-Risk, Non-Muscle Invasive Bladder Cancer
June 25, 2025
From enGene Holdings Inc.
Via Business Wire
News headline image
enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
June 17, 2025
From enGene Holdings Inc.
Via Business Wire
News headline image
enGene Reports Second Quarter 2025 Financial Results and Provides Business Update
June 12, 2025
From enGene Holdings Inc.
Via Business Wire
News headline image
enGene Announces the Resignation of its Chief Medical Officer
June 04, 2025
From enGene Holdings Inc.
Via Business Wire
News headline image
enGene to Present at the Jefferies Global Healthcare Conference
May 29, 2025
From enGene Holdings Inc.
Via Business Wire
News headline image
enGene Names Amy Pott as Chief Global Commercialization Officer
May 28, 2025
From enGene Holdings Inc.
Via Business Wire
News headline image
enGene to Participate in Upcoming Investor Conferences
April 29, 2025
From enGene Holdings Inc.
Via Business Wire
News headline image
enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
April 04, 2025
From enGene Holdings Inc.
Via Business Wire
News headline image
enGene to Present at the Stifel 2025 Virtual Targeted Oncology Forum
April 01, 2025
From enGene Holdings Inc.
Via Business Wire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap